Tunnelled versus straight intravitreal injection: Intraocular pressure changes, vitreous reflux, and patient discomfort

Retina

Volumn 29, Issue 8, 2009, Pages 1175-1181

  Knecht, Pascal Bruno ^a   Michels, Stephan ^a,b   Sturm, Veit ^a   Bosch, Martina Monika ^a   Menke, Marcel Nico ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Intraocular pressure; Intravitreal injection; Patient discomfort; Tunnelled scleral injection; Vitreous reflux

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EYE DISCOMFORT; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT SATISFACTION; SCORING SYSTEM; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RETINAL DISEASES; VITREOUS BODY;

EID: 70349105989     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181aade74     Document Type: Article

References (31)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Jiang Y, Liang X, Li X, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascu-larization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2008 Sept 18 [Epub ahead of print].
4. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008;25:438-443.
5. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007;55:451-455.
6. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-439.
7. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevaci-zumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
8. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bev-acizumab. Eye 2008;22:590-591.
9. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab
10. (Avastin[R]): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Oph-thalmol 2008;246:81-87.
11. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004; 24:676-698.
12. Mason JO, 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567.
13. Pallikaris IG, Kymionis GD, Ginis HS, et al. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci 2005;46:409-414.
14. Coden DJ, Freeman WR, Weinreb RN. Intraocular pressure response after pneumatic retinopexy. Ophthalmic Surg 1988; 19:667-669.
15. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.e1.
16. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcino-lone acetonide. Ophthalmology 2006;113:1174-1178.
17. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044-1047.
18. Lopez-Guajardo L, Del Valle FG, Moreno JP, Teus MA.
19. Reduction of pegaptanib loss during intravitreal delivery using an oblique injection technique. Eye 2008;22:430-433.
20. Lopez-Guajardo L, Pareja-Esteban J, Teus-Guezala MA. Oblique sclerotomy technique for prevention of incompetent wound closure in transconjunctival 25-gauge vitrectomy. Am J Ophthalmol 2006;141:1154-1156.
21. Rodrigues EB, Meyer CH, Grumann A Jr, et al. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 2007;143:1035-1037.
22. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988;14:9-17.
23. Freeman K, Smyth C, Dallam L, Jackson B. Pain measurement scales: a comparison of the visual analogue and faces rating scales in measuring pressure ulcer pain. J Wound Ostomy Continence Nurs 2001;28:290-296.
24. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
25. Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with Goldmann Applanation Tonometry. Invest Ophthalmol Vis Sci 2004;45:3118-3121.
26. Kniestedt C, Nee M, Stamper RL. Dynamic contour tonome-try: a comparative study on human cadaver eyes. Arch Oph-thalmol 2004;122:1287-1293.
27. Johannesson G, Hallberg P, Eklund A, Linden C. Pascal, ICare and Goldmann applanation tonometry-a comparative study Acta Ophthalmol 2008;86:614-621.
28. Salvetat ML, Zeppieri M, Tosoni C, Brusini P. Comparisons between Pascal dynamic contour tonometry, the TonoPen, and Goldmann applanation tonometry in patients with glaucoma. Acta Ophthalmol Scand 2007;85:272-279.
29. Kaderli B, Avci R. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Oph-thalmol 2006;16:718-721.
30. Kozak I, Dean A, Clark TM, et al. Prefilled syringe needles versus standard removable needles for intravitreous injection. Retina 2006;26:679-683.
31. Pulido JS, Pulido CM, Bakri SJ, et al. The use of 31-gauge needles and syringes for intraocular injections. Eye 2007;21:829-830.